Medicare approves next generation cancer testing

The Centers for Medicare and Medicaid Services (CMS) announced they will now cover the cost of next-generation sequencing (NCS) test for patients with advanced cancer. After FDA approved a cancer diagnostic test, FoundationOne CDx, the first NGS-based in vitro diagnostic text that is a companion diagnostic for 15 targeted therapies and can detect genetic mutations in 324 genes and two genomic signatures in any solid tumor.  Read article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or

Leave a Reply